<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017688</url>
  </required_header>
  <id_info>
    <org_study_id>MPOH07</org_study_id>
    <nct_id>NCT05017688</nct_id>
  </id_info>
  <brief_title>Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)</brief_title>
  <acronym>ORION</acronym>
  <official_title>PrOspective inteRventional Study Exploring the mIcrobiota recolONization in Steroid-Refractory Graft-versus-Host Disease Patients Receiving MaaT013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaaT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaaT Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the ORION study is to explore the changes of gut microbiota composition&#xD;
      following MaaT013 administration and its impact on the immune system in GVHD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The french regulatory authority ANSM approved in July 2019 the use of MaaT013, a pooled&#xD;
      microbiome-based enema formulation, under a formalized named-patient use program in France&#xD;
      called &quot;Autorisation Temporaire d'Utilisation - ATU nominative protocolisée - ATUn&quot; or Early&#xD;
      Access.&#xD;
&#xD;
      The ATUn is indicated to provide a benefit in the treatment of patients with grade III-IV&#xD;
      aGVHD:&#xD;
&#xD;
        -  In case of initial resistance to CS alone or in association or in case of failure to&#xD;
           other treaments&#xD;
&#xD;
        -  In first-line therapy in association with CS in case of steroid-dependance (inability to&#xD;
           taper CS dose &lt;0.5 mg/kg/d)&#xD;
&#xD;
        -  In case of digestive aGvHD with overlap syndrome The objective of the ORION study is to&#xD;
           explore the changes of gut microbiota composition following MaaT013 administration and&#xD;
           its impact on the immune system in GVHD patients.&#xD;
&#xD;
      Blood and stool samples will be collected at each visit which explained why the study is thus&#xD;
      categorized as research involving the human person with low risks and constraints clinical&#xD;
      trial (RIPH2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective interventional with low risks and constraints study (RIPH2)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of gut microbiota diversity</measure>
    <time_frame>inclusion (day 0) to month 6</time_frame>
    <description>Diversity of gut microbiota will be evaluated using alpha-diversity metric (Simpson or Shannon or Richness indice) throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of gut microbiota composition</measure>
    <time_frame>inclusion (day 0) to month 6</time_frame>
    <description>Sample comparisons will be performed using similarity metric such as Bray-Curtis, Jaccard distances, Sorensen, Pearson or Spearman indice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of gut microbiota composition (phylogenetic profiles)</measure>
    <time_frame>inclusion (day 0) to month 6</time_frame>
    <description>Gut microbiota composition will be evaluated with phylogenetic profiling. Relative abundance of bacterial taxa will be described at each visit throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between gut microbiota and immune parameters</measure>
    <time_frame>inclusion (day 0) to month 6</time_frame>
    <description>Multiparameter analyses will be performed to identify correlations between changes in gut microbiota composition and immune parameters (Citrulline, Zonulin, ST2, 3 indoxyl sulfate, Reg3a, Total antioxidant status, TGFb1.2.3., IL-1b, IL-2, sIL-2ra, IL-6, IL-8, IL10, IL17-A, IL-18, IFNg, TNFa, sCD14, MCP1, CCL25, CCL28, sCD30, CXCL10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota baseline characterization based on clinical response</measure>
    <time_frame>day 0</time_frame>
    <description>Stratification of patients will be based on response to MaaT013 treatment at day 28. Then gut microbiota composition will be described in responder versus non responder patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune parameters following MaaT013 administration</measure>
    <time_frame>inclusion (day 0) to month 6</time_frame>
    <description>Cytokines and immune parameters of interest (Citrulline, Zonulin, ST2, 3 indoxyl sulfate, Reg3a, Total antioxidant status,TGFb1.2.3., IL-1b, IL-2, sIL-2ra, IL-6, IL-8, IL10, IL17-A, IL-18, IFNg, TNFa, sCD14, MCP1, CCL25, CCL28, sCD30, CXCL10) will be measured in plasma/serum by Luminex and ELISA at each visit and compared to baseline.&#xD;
Results will be expressed as ratios on D0 value and heatmap.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Intestinal GVHD</condition>
  <condition>Steroid Refractory GVHD</condition>
  <arm_group>
    <arm_group_label>Patient population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The population of the study will be adult patients with GI-aGVHD grade III to IV undergoing MaaT013 treatment through named-patient use program ATUn (Early Access Program).&#xD;
Blood and stool samples will be collected at each visit to analyse the gut microbiota and the immune cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood and stool sample collection</intervention_name>
    <description>Collection of blood samples (10 mL) Collection of fecal samples (10g)</description>
    <arm_group_label>Patient population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥18 years old with Grade III-IV aGVHD with gut involvement undergoing&#xD;
             treatment with MaaT013 through named-patient use program ATUn / Early Access&#xD;
&#xD;
          -  Signature of informed and written consent by the subject or by the subject's legally&#xD;
             acceptable representative for patients under guardianship or trusteeship.&#xD;
&#xD;
          -  Affiliated or recipient from a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Vulnerable patients such as: minors, persons deprived of liberty, persons in Intensive&#xD;
             Care Unit unable to provide informed consent prior to the intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Guenounou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCT Oncopole</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie PLANTAMURA, PharmD, PhD</last_name>
    <phone>0663590186</phone>
    <phone_ext>0033</phone_ext>
    <email>eplantamura@maat-pharma.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>fecal microbiotherapy</keyword>
  <keyword>intestinal GvHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

